Development of a spherical (125)i-brachytherapy seed for its application in the treatment of eye and prostate cancer.
Palladium-coated silver beads of 0.5 mm (phi) were used to adsorb (125)I, encapsulated inside a titanium capsule by an Nd:YAG laser, for use as a brachytherapy source. Experimental conditions, such as feed activity, carrier concentration, and reaction time, were optimized for the maximum adsorption of (125)I. Uniform distribution of radioactivity on the source core was ascertained by the autoradiography technique. Leachability of (125)I was found to be <0.01%. The dose-rate constant of the new source was estimated to be 1.045 cGyh(-1)U(-1). This newly developed source could be an alternative to other (125)I sources.